These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 21878360)

  • 1. Neurotoxic/neuroprotective activity of haloperidol, risperidone and paliperidone in neuroblastoma cells.
    Gassó P; Mas S; Molina O; Bernardo M; Lafuente A; Parellada E
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Jan; 36(1):71-7. PubMed ID: 21878360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paliperidone protects SK-N-SH cells against glutamate toxicity via Akt1/GSK3β signaling pathway.
    Peng L; Zhang X; Cui X; Zhu D; Wu J; Sun D; Yue Q; Li Z; Liu H; Li G; Zhang J; Xu H; Liu F; Qin C; Li M; Sun J
    Schizophr Res; 2014 Aug; 157(1-3):120-7. PubMed ID: 24962437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the neurotoxic activity of typical and atypical neuroleptics: relevance to iatrogenic extrapyramidal symptoms.
    Gil-ad I; Shtaif B; Shiloh R; Weizman A
    Cell Mol Neurobiol; 2001 Dec; 21(6):705-16. PubMed ID: 12043843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paliperidone: new drug. Just a metabolite of risperidone, a neuroleptic soon off-patent.
    Prescrire Int; 2007 Dec; 16(92):236-7. PubMed ID: 18092400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Forty years of antipsychotic Drug research--from haloperidol to paliperidone--with Dr. Paul Janssen.
    Awouters FH; Lewi PJ
    Arzneimittelforschung; 2007; 57(10):625-32. PubMed ID: 18074755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurotoxic potential of haloperidol in comparison with risperidone: implication of Akt-mediated signal changes by haloperidol.
    Ukai W; Ozawa H; Tateno M; Hashimoto E; Saito T
    J Neural Transm (Vienna); 2004 Jun; 111(6):667-81. PubMed ID: 15168214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paliperidone: quo vadis?
    Citrome L
    Int J Clin Pract; 2007 Apr; 61(4):653-62. PubMed ID: 17343660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies on the acute toxicity, pharmacokinetics and pharmacodynamics of paliperidone derivatives--comparison to paliperidone and risperidone in mice and rats.
    Sun F; Su Z; Sui C; Zhang C; Yuan L; Meng Q; Teng L; Li Y
    Basic Clin Pharmacol Toxicol; 2010 Aug; 107(2):656-62. PubMed ID: 20662826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia.
    Fowler JA; Bettinger TL; Argo TR
    Clin Ther; 2008 Feb; 30(2):231-48. PubMed ID: 18343262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
    Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
    Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective effects of olanzapine and haloperidol on serum withdrawal-induced apoptosis in SH-SY5Y cells.
    Kim NR; Park SW; Lee JG; Kim YH
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):633-42. PubMed ID: 18055082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone.
    Canuso CM; Youssef EA; Bossie CA; Turkoz I; Schreiner A; Simpson GM
    Int Clin Psychopharmacol; 2008 Jul; 23(4):209-15. PubMed ID: 18545059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release.
    Pani L; Marchese G
    Expert Opin Drug Deliv; 2009 Mar; 6(3):319-31. PubMed ID: 19317589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antipsychotic-induced DRD2 upregulation and its prevention by α-lipoic acid in SH-SY5Y neuroblastoma cells.
    Deslauriers J; Lefrançois M; Larouche A; Sarret P; Grignon S
    Synapse; 2011 Apr; 65(4):321-31. PubMed ID: 20730801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Paliperidone, risperidone].
    Takeuchi K; Sanjo K; Sakai A
    Nihon Rinsho; 2013 Apr; 71(4):654-9. PubMed ID: 23678595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse effects of risperidone and haloperidol treatment in schizophrenia.
    Yen YC; Lung FW; Chong MY
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):285-90. PubMed ID: 14751424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia.
    Berwaerts J; Cleton A; Rossenu S; Talluri K; Remmerie B; Janssens L; Boom S; Kramer M; Eerdekens M
    J Psychopharmacol; 2010 Jul; 24(7):1011-8. PubMed ID: 19825908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ascorbic acid protects SH-SY5Y neuroblastoma cells from apoptosis and death induced by beta-amyloid.
    Huang J; May JM
    Brain Res; 2006 Jun; 1097(1):52-8. PubMed ID: 16725131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paliperidone extended-release for the treatment of schizophrenia.
    Marino J; Caballero J
    Pharmacotherapy; 2008 Oct; 28(10):1283-98. PubMed ID: 18823223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.